ASX announcements

Date Title
09/11/2015 2015 Annual General Meeting Chairman’s Address
24/11/2015 Breakthrough technology for high potency stem cells opens door for next generation cell therapies
07/12/2015 Corporate Presentation for Austrade Mission on Regenerative Medicine Opportunities in Japan
02/09/2015 Date of Annual General Meeting
31/08/2015 Financial year 2015 full-year results and business update presentation
27/10/2015 First patient safely treated in cancer vaccine trial
10/08/2015 First patient treated in Progenza stem cell trial for knee osteoarthritis
11/11/2015 Key patent granted for allogeneic stem cell technology platform
23/02/2015 New Director joins Regeneus Board of Directors
08/10/2015 Notice of Annual General Meeting 9 November 2015 and Explanatory Statement
15/12/2015 Patent granted for cancer vaccine technology
09/11/2015 Presentation to shareholders at 2015 AGM
19/02/2015 Regeneus 2015 Half Year Results
07/04/2015 Regeneus achieves key stem cell manufacturing milestone for clinical trial
26/11/2015 Regeneus initiates canine cancer vaccine trial on lymphoma at SASH
02/11/2015 Regeneus partners with leading animal health company on stem cell therapy for dogs
25/05/2015 Regeneus receives approval for personalised cancer immunotherapy trial
22/04/2015 Regeneus receives approval for Progenza stem cell trial for osteoarthritis
13/10/2015 Regeneus receives R&D tax incentive refund of $3.4m
31/08/2015 Regeneus reports 2015 full-year results and business update
09/03/2015 Regeneus reports positive preclinical results for off-the-shelf cell therapy treatment for osteoarthritis
23/03/2015 Regeneus to present at 3rd Annual Regenerative Medicine Investor Day March 25 in New York
07/12/2015 Regeneus to present at Austrade Mission on Regenerative Medicine Opportunities in Japan
04/09/2015 Restricted securities to be released from escrow
09/11/2015 Results of 2015 Regeneus Annual General Meeting
05/11/2015 Stem cells have positive results on early orthopaedic developmental disease in Yearling Thoroughbreds